Pharma, Healthcare Q3 Results Preview - Cost Pressures Have Started Abating: ICICI Securities
We expect pharma, healthcare companies under our coverage to report modest growth in Q3, supported by healthy domestic performance
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
We expect pharma and healthcare companies under our coverage to report modest growth in Q3 FY23, supported by healthy domestic performance.
Raw material and freight costs are expected to taper down slightly but still remain at elevated levels viz-a-viz pre-Covid level. Pricing pressures have started slowing down in the U.S. with the expectation of normalisation in coming months.
We expect Ebitda margin of our coverage companies to decline by 50 basis points YoY to 20.9%.
Healthcare segment (hospitals, diagnostics and devices) is likely to report healthy YoY performance driven by recovery in base business. Diagnostic companies are likely to witness a sequential decline with Q3 being a historically weak quarter for most companies.
Overall, we expect our coverage universe players to report 7.7%/5.3%/ YoY revenue/Ebitda growth and 7.2% decline in profit after tax, respectively.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.